Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Lung Cancer Année : 2019

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Dates et versions

hal-02273984 , version 1 (29-08-2019)

Identifiants

Citer

Christos Chouaid, Lionel Bensimon, Emilie Clay, Aurélie Millier, Laurie Levy-Bachelot, et al.. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩. ⟨hal-02273984⟩
70 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More